[The role of incretins. Type 2 diabetes with new beginnings].
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D000077270:Exenatide; D005749:Gastric Inhibitory Polypeptide / Q000008:administration & dosage / Q000627:therapeutic use*; D005934:Glucagon / Q000008:administration & dosage / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D011498:Protein Precursors / Q000008:administration & dosage / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D007328:Insulin; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D014688:Venoms; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide